FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2886757699> ?p ?o ?g. }

• W2886757699 endingPage "429" @default.
• W2886757699 startingPage "423" @default.
• W2886757699 abstract "The aim of this study was to examine continuation of subcutaneous and intramuscular depot medroxyprogesterone acetate (DMPA-SC and DMPA-IM) when administered by facility-based health workers in Burkina Faso and Village Health Teams (VHTs) in Uganda.Participants were family planning clients of health centers (Burkina Faso) or VHTs (Uganda) who had decided to initiate injectable use. Women selected DMPA-SC or DMPA-IM and study staff followed them for up to four injections (providing 12 months of pregnancy protection) to determine contraceptive continuation. Study staff interviewed women at their first injection (baseline), second injection, fourth injection and if they discontinued either product.Twelve-month continuation in Burkina Faso was 50% for DMPA-SC and 47.4% for DMPA-IM (p=.41, N=990, 492 DMPA-SC and 498 DMPA-IM). Twelve-month continuation in Uganda was 77.8% for DMPA-SC and 77.4% for DMPA-IM (p=.85, N=1224, 609 DMPA-SC and 615 DMPA-IM). Reasons for discontinuation of DMPA across groups in Burkina Faso included side effects (90/492, 18.3%), being late for injection (68/492, 13.8%) and refusal of spouse (51/492, 10.4%). Reasons for discontinuation in Uganda included being late for injection (65/229, 28.4%), received from non-VHT (50/229, 21.8%) and side effects (34/229, 14.8%). Increased age (adjusted hazard ratio=0.98, p=.01) and partner acceptance of family planning (adjusted hazard ratio=0.48, p<.001) had protective effects against discontinuation in Burkina Faso; we did not find statistically significant variables in Uganda.There is no difference in 12-month continuation (through four injections) between DMPA-SC and DMPA-IM whether from facility-based health workers in Burkina Faso or VHTs in Uganda. Continuation was higher through community-based distribution in Uganda than health facilities in Burkina Faso.The subcutaneous formulation of depot medroxyprogesterone acetate (DMPA-SC) is increasingly available in Family Planning 2020 countries. Use of DMPA-SC does not appear to change continuation relative to traditional intramuscular DMPA. Growing evidence of DMPA-SC's suitability for community-based distribution and self-injection may yield indirect benefits for contraceptive continuation and help reach new users." @default.
• W2886757699 created "2018-08-22" @default.
• W2886757699 creator A5004096695 @default.
• W2886757699 creator A5017247017 @default.
• W2886757699 creator A5018375635 @default.
• W2886757699 creator A5026743938 @default.
• W2886757699 creator A5034462540 @default.
• W2886757699 creator A5049853282 @default.
• W2886757699 creator A5053950461 @default.
• W2886757699 creator A5054623868 @default.
• W2886757699 creator A5056927282 @default.
• W2886757699 creator A5065143075 @default.
• W2886757699 creator A5065228522 @default.
• W2886757699 creator A5071052276 @default.
• W2886757699 creator A5077008460 @default.
• W2886757699 creator A5081152275 @default.
• W2886757699 creator A5081947591 @default.
• W2886757699 creator A5088496304 @default.
• W2886757699 date "2018-11-01" @default.
• W2886757699 modified "2023-10-09" @default.
• W2886757699 title "Continuation of subcutaneous or intramuscular injectable contraception when administered by facility-based and community health workers: findings from a prospective cohort study in Burkina Faso and Uganda" @default.
• W2886757699 cites W1983570073 @default.
• W2886757699 cites W2021822567 @default.
• W2886757699 cites W2075143578 @default.
• W2886757699 cites W2101902237 @default.
• W2886757699 cites W2129750327 @default.
• W2886757699 cites W2149328406 @default.
• W2886757699 cites W2260878706 @default.
• W2886757699 cites W2755351933 @default.
• W2886757699 cites W2793321151 @default.
• W2886757699 cites W2794120806 @default.
• W2886757699 cites W2795019219 @default.
• W2886757699 cites W2797337609 @default.
• W2886757699 doi "https://doi.org/10.1016/j.contraception.2018.08.007" @default.
• W2886757699 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6197835" @default.
• W2886757699 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30125558" @default.
• W2886757699 hasPublicationYear "2018" @default.
• W2886757699 type Work @default.
• W2886757699 sameAs 2886757699 @default.
• W2886757699 citedByCount "19" @default.
• W2886757699 countsByYear W28867576992018 @default.
• W2886757699 countsByYear W28867576992019 @default.
• W2886757699 countsByYear W28867576992020 @default.
• W2886757699 countsByYear W28867576992021 @default.
• W2886757699 countsByYear W28867576992023 @default.
• W2886757699 crossrefType "journal-article" @default.
• W2886757699 hasAuthorship W2886757699A5004096695 @default.
• W2886757699 hasAuthorship W2886757699A5017247017 @default.
• W2886757699 hasAuthorship W2886757699A5018375635 @default.
• W2886757699 hasAuthorship W2886757699A5026743938 @default.
• W2886757699 hasAuthorship W2886757699A5034462540 @default.
• W2886757699 hasAuthorship W2886757699A5049853282 @default.
• W2886757699 hasAuthorship W2886757699A5053950461 @default.
• W2886757699 hasAuthorship W2886757699A5054623868 @default.
• W2886757699 hasAuthorship W2886757699A5056927282 @default.
• W2886757699 hasAuthorship W2886757699A5065143075 @default.
• W2886757699 hasAuthorship W2886757699A5065228522 @default.
• W2886757699 hasAuthorship W2886757699A5071052276 @default.
• W2886757699 hasAuthorship W2886757699A5077008460 @default.
• W2886757699 hasAuthorship W2886757699A5081152275 @default.
• W2886757699 hasAuthorship W2886757699A5081947591 @default.
• W2886757699 hasAuthorship W2886757699A5088496304 @default.
• W2886757699 hasBestOaLocation W28867576991 @default.
• W2886757699 hasConcept C126322002 @default.
• W2886757699 hasConcept C131872663 @default.
• W2886757699 hasConcept C141071460 @default.
• W2886757699 hasConcept C144024400 @default.
• W2886757699 hasConcept C187212893 @default.
• W2886757699 hasConcept C19165224 @default.
• W2886757699 hasConcept C2776306185 @default.
• W2886757699 hasConcept C2777164284 @default.
• W2886757699 hasConcept C2777495918 @default.
• W2886757699 hasConcept C2778715236 @default.
• W2886757699 hasConcept C2779076696 @default.
• W2886757699 hasConcept C2908647359 @default.
• W2886757699 hasConcept C29456083 @default.
• W2886757699 hasConcept C2986817661 @default.
• W2886757699 hasConcept C71924100 @default.
• W2886757699 hasConcept C72563966 @default.
• W2886757699 hasConcept C99454951 @default.
• W2886757699 hasConceptScore W2886757699C126322002 @default.
• W2886757699 hasConceptScore W2886757699C131872663 @default.
• W2886757699 hasConceptScore W2886757699C141071460 @default.
• W2886757699 hasConceptScore W2886757699C144024400 @default.
• W2886757699 hasConceptScore W2886757699C187212893 @default.
• W2886757699 hasConceptScore W2886757699C19165224 @default.
• W2886757699 hasConceptScore W2886757699C2776306185 @default.
• W2886757699 hasConceptScore W2886757699C2777164284 @default.
• W2886757699 hasConceptScore W2886757699C2777495918 @default.
• W2886757699 hasConceptScore W2886757699C2778715236 @default.
• W2886757699 hasConceptScore W2886757699C2779076696 @default.
• W2886757699 hasConceptScore W2886757699C2908647359 @default.
• W2886757699 hasConceptScore W2886757699C29456083 @default.
• W2886757699 hasConceptScore W2886757699C2986817661 @default.
• W2886757699 hasConceptScore W2886757699C71924100 @default.
• W2886757699 hasConceptScore W2886757699C72563966 @default.
• W2886757699 hasConceptScore W2886757699C99454951 @default.
• W2886757699 hasFunder F4320306137 @default.

• next